Litera Selects New CEO Sheryl Hoskins
19.4.2022 16:00:00 EEST | Business Wire | Press release
Litera, a global leader in legal technology solutions, announced today that Avaneesh Marwaha has decided to step into a new role with the organization as Chairman of the Board. Following this appointment, Avaneesh and the Board are delighted to announce that Sheryl Hoskins will join the company as Litera’s new CEO. Hoskins brings extensive expertise in scaling enterprise software businesses and is uniquely suited to meet Litera’s ambitions to satisfy the growing needs of its customers in the global legal market.
Since Avaneesh joined Litera in 2016, the company has grown global users by over 1500%, annual revenue by 1200%, and headcount from 85 employees to over 850 worldwide. “It has been a tremendous honor to serve as Litera’s CEO, and I am incredibly proud of everything our team has accomplished together in just five years,” said Marwaha. “I am also incredibly excited to welcome Sheryl as our new CEO and look forward to working with her as she leads our business into the future. Sheryl brings distinctive experience scaling software companies and will take ownership of our ambitious strategy to enable the continued growth and success of our worldwide customer base.”
Litera’s Board, led by Hg Capital investors JB Brian, Ben Meyer, and Hector Guinness, said: “We greatly value and deeply appreciate Avaneesh’s leadership and his many contributions to Litera. We look forward to his continued contributions as Chairman of the Board and an equity investor. We are confident that Sheryl will build on the strong momentum the Litera team has created. Sheryl is a seasoned leader with a relentless focus on customer success and has significant experience working within public and private markets, operating efficiently at scale, and building world-class teams. We are delighted to welcome her as our next CEO.”
Hoskins has more than twenty years of experience in the global technology industry and a proven track record managing global teams. She spent the first decade of her career at General Electric and McKesson Corp, where she held domestic and international leadership roles. Most recently, Hoskins served as CEO of Upserve.
“I am honored to have been selected as Litera’s next CEO,” said Hoskins. “It is a privilege to be part of an organization that delivers innovative technology to over 96% of The Global 200 Law Firms. As the legal industry evolves, I believe Litera is in a position to transform the way legal teams and law firms use technology to drive digital transformation by delivering the best legal technology ecosystem. I will do my best to serve the business and its customers by helping enable our leaders and people to fulfill their passion for making a difference.”
Hoskins received a BS Degree in Electrical Engineering, an MBA in Marketing, and is a US Army veteran.
About Litera
Litera has been at the forefront of legal technology for 25+ years. As a global leader in workflow, AI-powered due diligence review and analysis, collaboration, data management, and governance solutions, Litera provides legal teams with streamlined technology for creating, analyzing, and managing their documents, deals, cases, and data. Litera’s solutions help law firms and corporate legal teams worldwide work more efficiently, accurately, and competitively to provide their clients with usable and actionable information. For more information about Litera, visit litera.com or follow the Company on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220418005535/en/
Contact information
Media Contact
Litera
Gayle Nixon
SVP, Marketing
E: gnixon@litera.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 15:29:00 EEST | Press release
Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level
Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom